Congress trades and big insider sales, sent the day they're filed. Free.
Open in TelegramOfficers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 5 | Russotti GregorySee Remarks | Grant or award | A | — 265.0K sh | Feb 4, 2026 |
| 5 | Carr DouglasSVP Finance & Operations | Grant or award | A | — 225.0K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 5 | Saldanha CraigChief Product Officer | Open-market sale · 10b5-1 plan | SELL | $33K 1,200 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 5 | Cowan ChadChief Scientific Officer | Grant or award | A | — 265.0K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 5 | Zojwalla NaseemCHIEF MEDICAL OFFICER | Grant or award | A | — 250.0K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 5 | Zojwalla NaseemCHIEF MEDICAL OFFICER | Grant or award | A | — 106.3K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 5 | Chuang Patrick T.Senior VP, Memory Design | Grant or award | A | — 20.0K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 5 | Pfeiffenberger BrentDirector, President and CEO | Grant or award | A | — 945.0K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 5 | Naude PierreDirector | Grant or award | A | — 3,516 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 5 | Bharucha DavidChief Medical Officer | Grant or award | A | — 204.0K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 5 | Heeson LeeEVP, Head of Incyte Intl | Tax withholding | F | $11K 111 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 5 | Bharucha DavidChief Medical Officer | Grant or award | A | — 136.0K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 5 | Randhawa SimratEVP, Head of R&D | Grant or award | A | — 150.0K sh | Feb 4, 2026 traded Feb 3, 2026 |
| 5 | Novack Jeffrey AdamSecretary and General Counsel | Grant or award | A | — 4,342 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 5 | Vultaggio VincentPAO and PFO | Open-market sale · 10b5-1 plan | SELL | $6,477 2,540 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 5 | Nelson Jeffrey EdwardChief Operating Officer | Grant or award | A | — 136.0K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 5 | Nelson Jeffrey EdwardChief Operating Officer | Grant or award | A | — 204.0K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 3 | Remer Eric RichardDirector, Chief Executive Officer | Open-market sale · 10b5-1 plan | SELL | $20K 1,700 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 3 | Remer Eric RichardDirector, Chief Executive Officer | Open-market sale · 10b5-1 plan | SELL | $30K 2,797 sh | Feb 4, 2026 traded Feb 4, 2026 |
| 3 | Bachrodt AmySVP, Finance | Option exercise · 10b5-1 plan | M | $50K 4,844 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 2 | Allaire JeremyDirector, Chairman and CEO | Option exercise | M | — 15.2K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 2 | Holleran KevinDirector, President and CEO | Option exercise · 10b5-1 plan | M | $73K 52.4K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 2 | Allaire JeremyDirector, Chairman and CEO | Option exercise | M | — 6,017 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 2 | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF | Grant or award | A | — 250.0K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 2 | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF | Grant or award | A | — 106.3K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 2 | Allaire JeremyDirector, Chairman and CEO | Option exercise | M | — 6,742 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 1 | Sieffert Kristen NPresident | Open-market sale · 10b5-1 plan | SELL | $17K 750 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 1 | Kozarich John WDirector | Open-market sale · 10b5-1 plan | SELL | $75K 381 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 1 | Vultaggio VincentPAO and PFO | Open-market sale · 10b5-1 plan | SELL | $1,398 556 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 1 | Barrett David MichaelDirector, Chief Executive Officer | Open-market sale · 10b5-1 plan | SELL | $44K 30.0K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 0 | Okupe OluyemiChief Financial Officer | Option exercise · 10b5-1 plan | M | — 5,262 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 0 | Wampler Kira SchererDirector | Option exercise · 10b5-1 plan | M | — 2,000 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 0 | Tang StanleyDirector | Other acquisition or disposition · 10b5-1 plan | J | — 45.4K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 0 | Bernstein HaroldPresident, R&D & CMO | Option exercise · 10b5-1 plan | M | — 15.0K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 0 | Wampler Kira SchererDirector | Option exercise · 10b5-1 plan | M | — 2,000 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 0 | Alpern Paul LVP and General Counsel | Option exercise · 10b5-1 plan | M | $2,800 5,000 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 0 | Holleran KevinDirector, President and CEO | Option exercise · 10b5-1 plan | M | — 52.4K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 0 | Alpern Paul LVP and General Counsel | Option exercise · 10b5-1 plan | M | — 5,000 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 0 | Fang AndyDirector | Other acquisition or disposition · 10b5-1 plan | J | — 10.0K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 0 | Wampler Kira SchererDirector | Derivative conversion · 10b5-1 plan | C | — 2,000 sh | Feb 4, 2026 traded Feb 2, 2026 |